Global Iohexol API Market Growth 2023-2029

Global Iohexol API Market Growth 2023-2029

Iohexol was first listed in Norway and Sweden in 1982. It is a kind of second-generation non-ionic monomeric contrast agent. Iopromide, Iomeprol, etc. Iohexol has low osmotic pressure, low toxicity to the nervous system, low contrast density, and good tolerance. It can be used for angiography, subarachnoid angiography, coronary angiography, spinal cord and femoral joints, urology angiography, and enhanced CT scanning. Etc., is the "gold standard" for evaluating various X-ray contrast agents in the medical community.

LPI (LP Information)' newest research report, the “Iohexol API Industry Forecast” looks at past sales and reviews total world Iohexol API sales in 2022, providing a comprehensive analysis by region and market sector of projected Iohexol API sales for 2023 through 2029. With Iohexol API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Iohexol API industry.

This Insight Report provides a comprehensive analysis of the global Iohexol API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Iohexol API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Iohexol API market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Iohexol API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Iohexol API.

The global Iohexol API market size is projected to grow from US$ 495.1 million in 2022 to US$ 803.8 million in 2029; it is expected to grow at a CAGR of 803.8 from 2023 to 2029.

Global key manufacturers of Iohexol API include GE Healthcare, Otsuka Chemicals, Starry, etc. Global top three manufacturers hold a share about 85%. Europe is the largest market of Iohexol API, holds a share over 60%. In terms of product, the Original Drug holds a larger segment, with a share over 80%. And in terms of application, the largest application is Hospitals, with a share of over 90%.

This report presents a comprehensive overview, market shares, and growth opportunities of Iohexol API market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Original Drug
Generic Drug

Segmentation by application
Hospitals
Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GE Healthcare
Otsuka Chemicals
Justesa Imagen
Starry Pharmaceutical
Haichang Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Iohexol API market?

What factors are driving Iohexol API market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Iohexol API market opportunities vary by end market size?

How does Iohexol API break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.